Difference between revisions of "Stub"
Jump to navigation
Jump to search
m (→TG+Bev) |
|||
| Line 77: | Line 77: | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bevacizumab (Avastin)]] | *[[Bevacizumab (Avastin)]] | ||
| + | |||
| + | ==MFL== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | MFL: '''<u>M</u>'''ethyl-lomustine (MeCCNU), 5-'''<u>F</u>U''' & '''<u>L</u>'''euco'''<u>V</u>'''orin (Folinic acid) | ||
| + | ===Regimen=== | ||
| + | ====Chemotherapy==== | ||
| + | *[[Semustine (MeCCNU)]] | ||
| + | *[[Fluorouracil (5-FU)]] | ||
| + | *[[Folinic acid (Leucovorin)]] | ||
==TG+Bev== | ==TG+Bev== | ||
Revision as of 16:08, 30 July 2020
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology.
CE & Ipilimumab
| back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
CE & Thalidomide
| back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
EP & Ipilimumab
| back to top |
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
| back to top |
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Hormonotherapy
Radiotherapy
- Concurrent thoracic radiation therapy
FULV & Trimetrexate
| back to top |
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
Ixabepilone & Bevacizumab
| back to top |
Regimen
Chemotherapy
Targeted therapy
MFL
| back to top |
MFL: Methyl-lomustine (MeCCNU), 5-FU & LeucoVorin (Folinic acid)
Regimen
Chemotherapy
TG+Bev
| back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
| back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab